Update on the ROADMAP clinical trial report: Olmesartan for the prevention or delay of microalbuminuria development in Type 2 diabetes

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 9, 2012, Pages 1087-1092

  Chatzikyrkou, Christos ^a   Menne, Jan ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

albuminuria; angiotensin II type 1 receptor blockers; angiotensin converting enzyme blockers; cardiovascular risk; diabetic nephropathy; hypertension; microalbuminuria; renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR; OLMESARTAN; PLACEBO;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; HUMAN; HYPOTENSION; LONG TERM CARE; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; IMIDAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAZOLES;

EID: 84867959724     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.100     Document Type: Review

References (29)

1. Matsushita K, van der Velde M, Astor BC et al.; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375(9731), 2073-2081 (2010)
2. van der Velde M, Matsushita K, Coresh J et al.; Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 79(12), 1341-1352 (2011)
3. Gansevoort RT, Matsushita K, van der Velde M et al.; Chronic Kidney Disease Prognosis Consortium. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 80(1), 93-104 (2011)
4. Hemmelgarn BR, Manns BJ, Lloyd A et al.; Alberta Kidney Disease Network. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303(5), 423-429 (2010)
5. Bello AK, Hemmelgarn B, Lloyd A et al.; Alberta Kidney Disease Network. Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes. Clin. J. Am. Soc. Nephrol. 6(6), 1418-1426 (2011)
6. Muntner P, Bowling CB, Gao L et al. Age-specific association of reduced estimated glomerular filtration rate and albuminuria with all-cause mortality. Clin. J. Am. Soc. Nephrol. 6(9), 2200-2207 (2011)
7. Levey AS, de Jong PE, Coresh J et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 80(1), 17-28 (2011)
8. Tonelli M, Muntner P, Lloyd A et al.; Alberta Kidney Disease Network. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann. Intern. Med. 154(1), 12-21 (2011)
9. Brantsma AH, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT; PREVEND Study Group. Extended prognostic value of urinary albumin excretion for cardiovascular events. J. Am. Soc. Nephrol. 19(9), 1785-1791 (2008)
10. Schmieder RE, Mann JF, Schumacher H et al.; ONTARGET Investigators. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J. Am. Soc. Nephrol. 22(7), 1353-1364 (2011)
11. Menne J, Chatzikyrkou C, Haller H. Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockade. J. Hypertens. 28(10), 1983-1994 (2010)
12. Ruggenenti P, Fassi A, Ilieva AP et al.; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in Type 2 diabetes. N. Engl. J. Med. 351(19), 1941-1951 (2004) (Pubitemid 39447135)
13. Bilous R, Chaturvedi N, Sjølie AK et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann. Intern. Med. 151(1), 11-20, W3 (2009)
14. Mann JF, Schmieder RE, Dyal L et al.; TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Effect of telmisartan on renal outcomes: a randomized trial. Ann. Intern. Med. 151(1), 1-10, W1 (2009)
15. Mauer M, Zinman B, Gardiner R et al. Renal and retinal effects of enalapril and losartan in Type 1 diabetes. N. Engl. J. Med. 361(1), 40-51 (2009)
16. Haller H, Ito S, Izzo JL Jr et al.; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in Type 2 diabetes. N. Engl. J. Med. 364(10), 907-917 (2011)
17. Haller H, Viberti GC, Mimran A et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J. Hypertens. 24(2), 403-408 (2006) (Pubitemid 43348255)
18. Ritz E, Viberti GC, Ruilope LM et al. Determinants of urinary albumin excretion within the normal range in patients with Type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 53(1), 49-57 (2010)
19. Menne J, Izzo JL Jr, Ito S et al.; ROADMAP investigators. Prevention of microalbuminuria in patients with Type 2 diabetes and hypertension. J. Hypertens. 30(4), 811-818; discussion 818 (2012)
20. Griffin SJ, Borch-Johnsen K, Davies MJ et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with Type 2 diabetes detected by screening (ADDITIONEurope): a cluster-randomised trial. Lancet 378(9786), 156-167 (2011)
21. Seshasai SR, Kaptoge S, Thompson A et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 364(9), 829-841 (2011)
22. Preiss D, Sattar N, McMurray JJ. A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. Am. Heart J. 161(1), 210-219. e1 (2011)
23. Messerli FH, Mancia G, Conti CR et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann. Intern. Med. 144(12), 884-893 (2006) (Pubitemid 46768128)
24. Bangalore S, Messerli FH, Wun CC et al.; Treating to New Targets Steering Committee and Investigators. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur. Heart J. 31(23), 2897-2908 (2010)
25. Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP; PROVE IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation 122(21), 2142-2151 (2010)
26. Sleight P, Redon J, Verdecchia P et al.; ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J. Hypertens. 27(7), 1360-1369 (2009)
27. Mancia G, Laurent S, Agabiti-Rosei E et al.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27(11), 2121-2158 (2009)
28. Mann JF, Gerstein HC, Yi QL et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J. Am. Soc. Nephrol. 14(3), 641-647 (2003) (Pubitemid 36246007)
29. de Galan BE, Perkovic V, Ninomiya T et al.; ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in Type 2 diabetes. J. Am. Soc. Nephrol. 20(4), 883-892 (2009)